In vitro methods to assess drug precipitation

International Journal of Pharmaceutics

Volumn 393, Issue 1-2, 2010, Pages 1-16

  Dai, Wei Guo ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Drug precipitation; In vitro precipitation assay; Intravenous formulation; Oral formulation

Indexed keywords

ACICLOVIR; ADRENALIN; AMIODARONE; ATROPINE; BISANTRENE; BRETYLIUM TOSYLATE; CELECOXIB; CINNARIZINE; CIPROFLOXACIN; CREMOPHOR; DIAZEPAM; DILTIAZEM; DIPYRIDAMOLE; DITEKIREN; DOBUTAMINE; DOPAMINE; FENOFIBRATE; FLAVOPIRIDOL; FLIBANSERIN; FUROSEMIDE; GLUCOSE; LEFRADAFIBAN; LIDOCAINE; NAFCILLIN; OFLOXACIN; PACLITAXEL; PHENYTOIN; PHYTOMENADIONE; PROPOFOL; UNINDEXED DRUG;

AREA UNDER THE CURVE; DILUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EXPOSURE; DRUG FORMULATION; DRUG RESEARCH; DRUG SOLUBILITY; DRUG TISSUE LEVEL; HUMAN; IN VITRO STUDY; LIPOLYSIS; NONHUMAN; PHLEBITIS; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; CHEMICAL PRECIPITATION; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; EQUIPMENT DESIGN; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; KINETICS; MINIATURIZATION; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 77953363188     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.03.040     Document Type: Review

References (141)

1. Alsenz J., Kansy M. High throughput solubility measurement in drug discovery and development. Adv. Drug Deliv. Rev. 2007, 59:546-567.
2. Alsenz J., Meister E., Haenel E. Development of a partially automated solubility screening (PASS) assay for early drug development. J. Pharm. Sci. 2007, 96:1748-1762.
3. Alvarez-Nunez F.A., Yalkowsky S.H. Buffer capacity and precipitation control of pH solubilized phenytoin formulations. Int. J. Pharm. 1999, 185:45-49.
4. Avis, K.E., Lachman, L., Lieberman, H.A. (Eds.), 1986. Pharmaceutical Dosage Forms: Parenter. Med. Vol. 2.
5. Bai G., Armenante P.M. Velocity distribution and shear rate variability resulting from changes in the impeller location in the USP dissolution testing apparatus II. Pharm. Res. 2008, 25:320-336.
6. Bai G., Armenante P.M., Plank R.V., Gentzler M., Ford K., Harmon P. Hydrodynamic investigation of USP dissolution test apparatus II. J. Pharm. Sci. 2007, 96:2327-2349.
7. Baxter J.L., Kukura J., Muzzio F.J. Hydrodynamics-induced variability in the USP apparatus II dissolution test. Int. J. Pharm. 2005, 292:17-28.
8. Blanquet S., Zeijdner E., Beyssac E., Meunier J.-P., Denis S., Havenaar R., Alric M. A dynamic artificial gastrointestinal system for studying the behavior of orally administered drug dosage forms under various physiological conditions. Pharm. Res. 2004, 21:585-591.
9. Bolger M.B., Gilman T.M., Fraczkiewicz R., Steere B., Woltosz W.S. Predicting drug absorption by computational methods. Cell Cult. Models Biol. Barriers 2002, 353-377.
10. Buck, M., Tsukamoto, T., Kvols, L.K., Kovach, J.S., 1985. Pharmacology studies of bisantrene, a poorly soluble anticancer drug, formulated in a lipid emulsion. Recent Adv. Chemother., Proc. Int. Congr. Chemother., 14th: Anticancer Sect. 1, 540-541.
11. Cammarn S.R., Sakr A. Predicting dissolution via hydrodynamics: salicylic acid tablets in flow through cell dissolution. Int. J. Pharm. 2000, 201:199-209.
12. Carvalho-Silva B., Moreira-Campos L.M., Nunan E.A., Vianna-Soares C.D., Araujo-Alves B.L., Cesar I.C., Pianetti G.A. Optimization and statistical evaluation of dissolution tests for indinavir sulfate capsules. Farmaco 2004, 59:921-927.
13. Chen H., Zhang Z., Almarsson O., Marier J.-F., Berkovitz D., Gardner C.R. A novel, lipid-free nanodispersion formulation of propofol and its characterization. Pharm. Res. 2005, 22:356-361.
14. Chen H., Zhang Z., McNulty C., Olbert C., Yoon H.J., Lee J.W., Kim S.C., Seo M.H., Oh H.S., Lemmo A.V., Ellis S.J., Heimlich K. A high-throughput combinatorial approach for the discovery of a cremophor EL-free paclitaxel formulation. Pharm. Res. 2003, 20:1302-1308.
15. Chen X.-Q., Venkatesh S. Miniature device for aqueous and non-aqueous solubility measurements during drug discovery. Pharm. Res. 2004, 21:1758-1761.
16. Christensen J.O., Schultz K., Mollgaard B., Kristensen H.G., Mullertz A. Solubilization of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerols. Eur. J. Pharm. Sci. 2004, 23:287-296.
17. Corrigan O.I., Devlin Y., Butler J. Influence of dissolution medium buffer composition on ketoprofen release from ER products and in vitro-in vivo correlation. Int. J. Pharm. 2003, 254:147-154.
18. Cox J.W., Sage G.P., Wynalda M.A., Ulrich R.G., Larson P.G., Su C.C. Plasma compatibility of injectables: comparison of intravenous U-74006F, a 21-aminosteroid antioxidant, with Dilantin brand of parenteral phenytoin. J. Pharm. Sci. 1991, 80:371-375.
19. Cuine Jean F., McEvoy Claire L., Charman William N., Pouton Colin W., Edwards Glenn A., Benameur H., Porter Christopher J.H. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J. Pharm. Sci. 2008, 97:995-1012.
20. Cuine J.F., Charman W.N., Pouton C.W., Edwards G.A., Porter C.J.H. Increasing the proportional content of surfactant (cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs. Pharm. Res. 2007, 24:748-757.
21. D'Arcy D.M., Corrigan O.I., Healy A.M. Hydrodynamic simulation (computational fluid dynamics) of asymmetrically positioned tablets in the paddle dissolution apparatus: impact on dissolution rate and variability. J. Pharm. Pharmacol. 2005, 57:1243-1250.
22. D'Arcy D.M., Corrigan O.I., Healy A.M. Evaluation of hydrodynamics in the basket dissolution apparatus using computational fluid dynamics-dissolution rate implications. Eur. J. Pharm. Sci. 2006, 27:259-267.
23. Dahan A., Hoffman A. Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: correlation with in vivo data and the relationship to intra-enterocyte processes in rats. Pharm. Res. 2006, 23:2165-2174.
24. Dahan A., Hoffman A. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Eur. J. Pharm. Biopharm. 2007, 67:96-105.
25. Dahan A., Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J. Controll. Rel. 2008, 129:1-10.
26. Dai W.-G., Dong L.C., Li S., Deng Z. Combination of Pluronic/Vitamin E TPGS as a potential inhibitor of drug precipitation. Int. J. Pharm. 2008, 355:31-37.
27. Dai W.-G., Dong L.C., Li S., Pollock-Dove C., Chen J., Mansky P., Eichenbaum G. Parallel screening approach to identify solubility-enhancing formulations for improved bioavailability of a poorly water-soluble compound using milligram quantities of material. Int. J. Pharm. 2007, 336:1-11.
28. Dai W.-G., Dong L.C., Shi X., Nguyen J., Evans J., Xu Y., Creasey A.A. Evaluation of drug precipitation of solubility-enhancing liquid formulations using milligram quantities of a new molecular entity (NME). J. Pharm. Sci. 2007, 96(11):2957-2969.
29. Dai W.-G., Pollock-Dove C., Dong L.C., Li S. Advanced screening assays to rapidly identify solubility-enhancing formulations: high-throughput, miniaturization and automation. Adv. Drug Deliv. Rev. 2008, 60:657-672.
30. Dannenfelser R.-M., Surakitbanharn Y., Tabibi S.E., Yalkowsky S.H. Parenteral formulation of flavopiridol (NSC-649890). PDA J. Pharm. Sci. Technol. 1996, 50:356-359.
31. Davio S.R., McShane M.M., Kakuk T.J., Zaya R.M., Cole S.L. Precipitation of the renin inhibitor Ditekiren upon iv infusion; in vitro studies and their relationship to in vivo precipitation in the cynomolgus monkey. Pharm. Res. 1991, 8:80-83.
32. Derendorf H., Drehsen G., Rohdewald P. In vivo-in vitro correlations of salicylate saliva levels and continuous flow cell dissolution rates. Int. J. Pharm. 1983, 15:167-175.
33. Dressman J., Schamp K., Beltz K., Alsenz J. Characterizing release from lipid-based formulations. Drugs Pharm. Sci. 2007, 170:241-255.
34. Dressman J.B., Amidon G.L., Reppas C., Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 1998, 15:11-22.
35. Dressman J.B., Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci. 2000, 11:S73-S80.
36. Emara L.H., El-Menshawi B.S., Estefan M.Y. In vitro-in vivo correlation and comparative bioavailability of vincamine in prolonged-release preparations. Drug Dev. Ind. Pharm. 2000, 26:243-251.
37. Falchuk K.H., Peterson L., McNeil B.J. Microparticulate-induced phlebitis. Its prevention by in-line filtration. New England J. Med. 1985, 312:78-82.
38. Fatouros D.G., Mullertz A. Using in vitro dynamic lipolysis modeling as a tool for exploring IVIVC relationships for oral lipid-based formulations. Drugs Pharm. Sci. 2007, 170:257-271.
39. Fatouros D.G., Mullertz A. In vitro lipid digestion models in design of drug delivery systems for enhancing oral bioavailability. Expert Opin. Drug Metab. Toxicol. 2008, 4:65-76.
40. Galia E., Nicolaides E., Horter D., Lobenberg R., Reppas C., Dressman J.B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 1998, 15:698-705.
41. Gao P., Akrami A., Alvarez F., Hu J., Li L., Ma C., Surapaneni S. Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption. J. Pharm. Sci. 2009, 98:516-528.
42. Gardner C. Drug candidate selection: the role of physical chemistry and material science in form and formulation. Bull. Tech. Gattefosse 2005, 9-18.
43. Gardner C.R., Almarsson O., Chen H., Morissette S., Peterson M., Zhang Z., Wang S., Lemmo A., Gonzalez-Zugasti J., Monagle J., Marchionna J., Ellis S., McNulty C., Johnson A., Levinson D., Cima M. Application of high throughput technologies to drug substance and drug product development. Comput. Chem. Eng. 2004, 28:943-953.
44. Gardner C.R., Walsh C.T., Almarsson O. Drugs as materials: valuing physical form in drug discovery. Nat. Rev. Drug Discov. 2004, 3:926-934.
45. Greenfield J.C., Loux S.J., Sood V.K., Jenkins K.M., Davio S.R. In vitro evaluation of the plasma and blood compatibility of a parenteral formulation for ditekiren, a novel renin inhibitor pseudopeptide. Pharm. Res. 1991, 475-479.
46. Grove M., Mullertz A. Liquid self-microemulsifying drug delivery systems. Drugs Pharm. Sci. 2007, 170:107-127.
47. Gu C.-H., Rao D., Gandhi R.B., Hilden J., Raghavan K. Using a novel multicompartment dissolution system to predict the effect of gastric pH on the oral absorption of weak bases with poor intrinsic solubility. J. Pharm. Sci. 2005, 94:199-208.
48. Guzman H.R., Tawa M., Zhang Z., Ratanabanangkoon P., Shaw P., Gardner C.R., Chen H., Moreau J.-P., Almarsson O., Remenar J.F. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J. Pharm. Sci. 2007, 96:2686-2702.
49. Hauss D.J. Oral lipid-based formulations. Adv. Drug Deliv. Rev. 2007, 59:667-676.
50. Hecker J.F., Fisk G.C., Lewis G.B. Phlebitis and extravasation (" tissuing" ) with intravenous infusions. Med. J. Aust. 1984, 140:658-660.
51. Hoener B.-A., Benet L.Z. Factors influencing drug absorption and drug availability. Drugs Pharm. Sci. 2002, 121:93-117.
52. Ikegami K., Tagawa K., Kobayashi M., Osawa T. Prediction of in vivo drug release behavior of controlled-release multiple-unit dosage forms in dogs using a flow-through type dissolution test method. Int. J. Pharm. 2003, 258:31-43.
53. Irwin W.J., Iqbal M. Bropirimine formulation: the dynamic testing of injections. Int. J. Pharm. 1992, 83:241-249.
54. Jannin V., Musakhanian J., Marchaud D. Approaches for the development of solid and semi-solid lipid-based formulations. Adv. Drug Deliv. Rev. 2008, 60:734-746.
55. Johnson J.L.H., Yalkowsky S.H. Reformulation of a new vancomycin analog: an example of the importance of buffer species and strength. AAPS PharmSciTech 2006, 7:E5.
56. Johnson J.L.H., He Y., Yalkowsky S.H. Prediction of precipitation-induced phlebitis: a statistical validation of an in vitro model. J. Pharm. Sci. 2003, 92:1574-1581.
57. Johnson K.C. Dissolution and absorption modeling: model expansion to simulate the effects of precipitation, water absorption, longitudinally changing intestinal permeability, and controlled release on drug absorption. Drug Dev. Ind. Pharm. 2003, 29:833-842.
58. Johnson K.C. Dissolution: fundamentals of in vitro release and the biopharmaceutics classification system. Drugs Pharm. Sci. 2007, 165:1-28.
59. Kaukonen A.M., Boyd B.J., Charman W.N., Porter C.J.H. Drug solubilization behavior during in vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids. Pharm. Res. 2004, 21:254-260.
60. Kaukonen A.M., Boyd B.J., Porter C.J.H., Charman W.N. Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulations. Pharm. Res. 2004, 21:245-253.
61. Kim M.-S., Jin S.-J., Kim J.-S., Park H.J., Song H.-S., Neubert R.H.H., Hwang S.-J. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur. J. Pharm. Biopharm. 2008, 69:454-465.
62. Kobayashi M., Sada N., Sugawara M., Iseki K., Miyazaki K. Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract. Int. J. Pharm. 2001, 221:87-94.
63. Kostewicz E.S., Wunderlich M., Brauns U., Becker R., Bock T., Dressman Jennifer B. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J. Pharm. Pharmacol. 2004, 56:43-51.
64. Kostewicz E.S., Brauns U., Becker R., Dressman J.B. Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharm. Res. 2002, 19:345-349.
65. Kovach J.S., Buck M., Tsukamoto T., Odegaard A., Lieber M.M. Regional targeting of bisantrene by directed intravascular precipitation. Cancer Chemother. Pharmacol. 1985, 15:192-195.
66. Kukura J., Baxter J.L., Muzzio F.J. Shear distribution and variability in the USP Apparatus 2 under turbulent conditions. Int. J. Pharm. 2004, 279:9-17.
67. Li P., Patel H., Tabibi S.E., Vishnuvajjala R., Yalkowsky S.H. Evaluation of intravenous flavopiridol formulations. PDA J. Pharm. Sci. Technol. 1999, 53:137-140.
68. Li P., Vishnuvajjala R., Tabibi S.E., Yalkowsky S.H. Evaluation of in vitro precipitation methods. J. Pharm. Sci. 1998, 87:196-199.
69. Lieber M.M., Welch T.J., Johnson C.M., Farrow G.M., Buck M., Kovach J.S. Directed intravascular precipitation of bisantrene for pelvic malignant lesions: preclinical studies. Mayo Clin. Proc. Mayo Clinic 1986, 61:173-179.
70. Liu R. Water-Insoluble Drug Formation 2000, Interpharm Press, Buffalo Grove.
71. Lu A.T.K., Frisella M.E., Johnson K.C. Dissolution modeling: factors affecting the dissolution rates of polydisperse powders. Pharm. Res. 1993, 10:1308-1314.
72. MacGregor K.J., Embleton J.K., Lacy J.E., Perry E.A., Solomon L.J., Seager H., Pouton C.W. Influence of lipolysis on drug absorption from the gastrointestinal tract. Adv. Drug Deliv. Rev. 1997, 25:33-46.
73. Mansky P., Dai W.-G., Li S., Pollock-Dove C., Daehne K., Dong L., Eichenbaum G. Screening method to identify preclinical liquid and semi-solid formulations for low solubility compounds: miniaturization and automation of solvent casting and dissolution testing. J. Pharm. Sci. 2007, 96:1548-1563.
74. Markowsky S.J., Kohls P.R., Ehresman D., Leppik I. Compatibility and pH variability of four injectable phenytoin sodium products. Am. J. Hosp. Pharm. 1991, 48:510-514.
75. McCarthy L.G., Bradley G., Sexton James C., Corrigan Owen I., Healy Anne M. Computational fluid dynamics modeling of the paddle dissolution apparatus: agitation rate, mixing patterns, and fluid velocities. AAPS PharmSciTech 2004, 5:e31.
76. McCarthy L.G., Kosiol C., Healy Anne M., Bradley G., Sexton James C., Corrigan Owen I. Simulating the hydrodynamic conditions in the United States Pharmacopeia paddle dissolution apparatus. AAPS PharmSciTech 2003, 4:E22.
77. Mirza T., Joshi Y., Liu Q., Vivilecchia R. Evaluation of dissolution hydrodynamics in the USP, Peak and flat-bottom vessels using different solubility drugs. Dissolution Technol. 2005, 12:11-16.
78. Moeller H., Wirbitzki E. Special cases of dissolution testing using the flow-through system. S.T.P. Pharma. 1990, 6:657-662.
79. Moeller H., Wirbitzki E. Regulatory aspects of modified release dosage forms: special cases of dissolution testing using the flow-through system. Boll. Chim. Farm 1993, 132:105-115.
80. Mullertz A. Lipid-based drug delivery systems: choosing the right in vitro tools. Am. Pharm. Rev. 2007, 10. pp. 102, 104, 106-110.
81. Narazaki R., Sanghvi R., Yalkowsky S.H. Estimation of drug precipitation upon dilution of pH-controlled formulations. Mol. Pharmaceutics 2007, 4:550-555.
82. Narazaki R., Sanghvi R., Yalkowsky S.H. Estimation of drug precipitation upon dilution of pH-cosolvent solubilized formulations. Chem. Pharm. Bull. 2007, 55:1203-1206.
83. Nicklasson M., Wennergren B., Linberg J., Persson C., Ahlgren R., Palm B., Pettersson A., Wenngren L. A collaborative in vitro dissolution study using the flow-through method. Int. J. Pharm. 1987, 37:195-202.
84. Nicolaides E., Galia E., Efthymiopoulos C., Dressman J.B., Reppas C. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm. Res. 1999, 16:1876-1882.
85. Perng C.-Y., Kearney A.S., Palepu N.R., Smith B.R., Azzarano L.M. Assessment of oral bioavailability enhancing approaches for SB-247083 using flow-through cell dissolution testing as one of the screens. Int. J. Pharm. 2003, 250:147-156.
86. Persson E.M., Gustafsson A.-S., Carlsson A.S., Nilsson R.G., Knutson L., Forsell P., Hanisch G., Lennernaes H., Abrahamsson B. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm. Res. 2005, 22:2141-2151.
87. Pfeifle C.E., Adler D.S., Gannaway W.L. Phenytoin sodium solubility in three intravenous solutions. Am. J. Hosp. Pharm. 1981, 38:358-362.
88. Phillips J.G., Chen Y., Wakeling I.N. A flow-through dissolution approach to in vivo/in vitro correlation of adinazolam release from sustained-release formulations. Drug Dev. Ind. Pharm. 1989, 15:2177-2195.
89. Porter C.J.H., Charman W.N. In vitro assessment of oral lipid based formulations. Bull. Tech. Gattefosse 2001, 94:119-139.
90. Porter C.J.H., Kaukonen A.M., Boyd B.J., Edwards G.A., Charman W.N. susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm. Res. 2004, 21:1405-1412.
91. Porter C.J.H., Kaukonen A.M., Taillardat-Bertschinger A., Boyd B.J., O'Connor J.M., Edwards G.A., Charman W.N. Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine. J. Pharm. Sci. 2004, 93:1110-1121.
92. Porter C.J.H., Pouton C.W., Cuine J.F., Charman W.N. Enhancing intestinal drug solubilization using lipid-based delivery systems. Adv. Drug Deliv. Rev. 2008, 60:673-691.
93. Porter C.J.H., Trevaskis N.L., Charman W.N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. 2007, 6:231-248.
94. Porter C.J.H., Wasan K.M., Constantinides P. Lipid-based systems for the enhanced delivery of poorly water soluble drugs. Adv. Drug Deliv. Rev. 2008, 60:615-616.
95. Pouton C.W. Key issues when formulating hydrophobic drugs with lipids. Bull. Tech. Gattefosse 1999, 92:41-50.
96. Pouton C.W. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur. J. Pharm. Sci. 2000, 11:S93-S98.
97. Pouton C.W., Porter C.J.H. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv. Drug Deliv. Rev. 2008, 60:625-637.
98. Powis G., Kovach J.S. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis. Cancer Res. 1983, 43:925-929.
99. Prentis R.A., Lis Y., Walker S.R. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharmacol. 1988, 25:387-396.
100. Qureshi S.A. Improved drug dissolution and product characterization using a crescent-shaped spindle. J. Pharm. Pharmacol. 2004, 56:1135-1141.
101. Qureshi S.A. Comparative impact of stirring and shearing in drug dissolution testing with USP paddle and crescent-shaped spindles. Dissolution Technol. 2006, 13:25-30.
102. Qureshi S.A., Caille G., Brien R., Piccirilli G., Yu V., McGilveray I.J. Application of flow-through dissolution method for the evaluation of oral formulations of nifedipine. Drug Dev. Ind. Pharm. 1994, 20:1869-1882.
103. Ratanabanangkoon P., Guzman H., Almarsson O., Berkovitz D., Tokarcyzk S., Straughn A.B., Chen H. A high-throughput approach towards a novel formulation of fenofibrate in omega-3 oil. Eur. J. Pharm. Sci. 2008, 33:351-360.
104. Reymond J.P., Sucker H. In vitro model for ciclosporin intestinal absorption in lipid vehicles. Pharm. Res. 1988, 5:673-676.
105. Rost M., Quist P.O. Dissolution of USP prednisone calibrator tablets. Effects of stirring conditions and particle size distribution. J. Pharm. Biomed. Anal. 2003, 31:1129-1143.
106. Scholz A., Abrahamsson B., Diebold S.M., Kostewicz E., Polentarutti B.I., Ungell A.-L., Dressman J.B. Influence of hydrodynamics and particle size on the absorption of felodipine in labradors. Pharm. Res. 2002, 19:42-46.
107. Scholz A., Kostewicz E., Abrahamsson B., Dressman J.B. Can the USP paddle method be used to represent in-vivo hydrodynamics?. J. Pharm. Pharmacol. 2003, 55:443-451.
108. Schroeder H.G., DeLuca P.P. A study on the in vitro precipitation of poorly soluble drugs from nonaqueous vehicles in human plasma. Bull. Parenter. Drug Assoc. 1974, 28:1-14.
109. Seadeek C., Ando H., Bhattachar S.N., Heimbach T., Sonnenberg J.L., Blackburn A.C. Automated approach to couple solubility with final pH and crystallinity for pharmaceutical discovery compounds. J. Pharm. Biomed. Anal. 2007, 43:1660-1666.
110. Sek L. Use of in vitro lipid digestion models for assessing oral lipid formulations. Am. Pharm. Rev. 2007, 10. pp. 54, 56-58.
111. Sek L., Boyd B.J., Charman W.N., Porter C.J.H. Examination of the impact of a range of pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone. J. Pharm. Pharmacol. 2006, 58:809-820.
112. Sek L., Porter C.J.H., Kaukonen A.M., Charman W.N. Evaluation of the in-vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products. J. Pharm. Pharmacol. 2002, 54:29-41.
113. Serajuddin A.T.M., Sheen P.C., Mufson D., Bernstein D.F., Augustine M.A. Physicochemical basis of increased bioavailability of a poorly water-soluble drug following oral administration as organic solutions. J. Pharm. Sci. 1988, 77:325-329.
114. Shah V.P. The role of dissolution testing in the regulation of pharmaceuticals: the FDA perspective. Pharm. Dissolution Testing 2005, 81-96.
115. Simmons D.M. Characterization of the precipitates of poorly-water-soluble drugs and determination of the solubilities in human gastrointestinal fluids by microscopy. Drug Dev. Ind. Pharm. 1993, 19:1103-1112.
116. Stippler E., Kopp S., Dressman J.B. Comparison of US Pharmacopeia simulated intestinal fluid TS and phosphate standard buffer pH 6.8, TS of the International Pharmacopoeia with respect to their use in vitro dissolution testing. Dissolution Technol. 2004, 11:6-10.
117. Strickley R.G. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 2004, 21:201-230.
118. Sugano K., Kato T., Suzuki K., Keiko K., Sujaku T., Mano T. High throughput solubility measurement with automated polarized light microscopy analysis. J. Pharm. Sci. 2006, 95:2115-2122.
119. Sunesen V.H., Pedersen B.L., Kristensen H.G., Muellertz A. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. Eur. J. Pharm. Sci. 2005, 24:305-313.
120. Surakitbanharn Y., Simamora P., Ward G.H., Yalkowsky S.H. Precipitation of pH solubilized phenytoin. Int. J. Pharm. 1994, 109:27-33.
121. Tang L., Khan S.U., Muhammad N.A. Evaluation and selection of bio-relevant dissolution media for a poorly water-soluble new chemical entity. Pharm. Dev. Technol. 2001, 6:531-540.
122. Taniguchi T., Yamamoto K., Kobayashi T. The precipitate formed by thiopentone and vecuronium. Can. J. Anaesth. 1996, 43:511-513.
123. Taniguchi T., Yamamoto K., Kobayashi T. Precipitate formed by thiopentone and vecuronium causes pulmonary embolism. Can. J. Anaesth. 1998, 45:347-351.
124. Thoma K., Ziegler I. Development of an automated flow-trough dissolution system for poorly soluble drugs with poor chemical stability in dissolution media. Pharmazie 1998, 53:784-790.
125. Tsukamoto, T., Buck, M., Odegaard, A., Lieber, M., Kovach, J.S., 1985. Regional localization of an anticancer drug, bisantrene, by intentional intravascular precipitation. Recent Adv. Chemother., Proc. Int. Congr. Chemother., 14th: Anticancer Sect. 1, 538-539.
126. Turco S.J. Phlebitis associated with intravenous drug administration. Bull Parenter. Drug Assoc. 1975, 29:89-97.
127. Uppoor V.R.S. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J. Control. Rel. 2001, 72:127-132.
128. Vasanthavada M., Serajuddin A.T.M. Lipid-based self-emulsifying solid dispersions. Drugs Pharm. Sci. 2007, 170:149-183.
129. Vertzoni M., Fotaki N., Kostewicz E., Stippler E., Leuner C., Nicolaides E., Dressman J., Reppas C. Dissolution media simulating the intralumenal composition of the small intestine: Physiological issues and practical aspects. J. Pharm. Pharmacol. 2004, 56:453-462.
130. Ward G.H., Yalkowsky S.H. Studies in phlebitis. IV: injection rate and amiodarone-induced phlebitis. J. Parenter. Sci. Technol. 1993, 47:40-43.
131. Ward G.H., Yalkowsky S.H. Studies in phlebitis. V: Hemolysis as a model for phlebitis. J. Parenter. Sci. Technol. 1993, 47:44-46.
132. Ward G.H., Yalkowsky S.H. Studies in phlebitis. VI: dilution-induced precipitation of amiodarone HCl. J. Parenter. Sci. Technol. 1993, 47:161-165.
133. Wennergren B., Lindberg J., Nicklasson M., Nilsson G., Nyberg G., Ahlgren R., Persson C., Palm B. A collaborative in vitro dissolution study: comparing the flow-through method with the USP paddle method using USP prednisone calibrator tablets. Int. J. Pharm. 1989, 53:35-41.
134. White M., Yalkowsky S.H. Studies in phlebitis. III. Evaluation of diazepam and phenytoin. Pharm. Res. 1991, 8:1341-1342.
135. Wyttenbach N., Alsenz J., Grassmann O. miniaturized assay for solubility and residual solid screening (SORESOS) in early drug development. Pharm. Res. 2007, 24:888-898.
136. Yalkowsky S.H. Solubility and Solubilization in Aqueous Media 2000, Oxford University Press.
137. Yalkowsky S.H., Krzyzaniak J.F., Ward G.H. Formulation-related problems associated with intravenous drug delivery. J. Pharm. Sci. 1998, 87:787-796.
138. Yalkowsky S.H., Valvani S.C. Precipitation of solubilized drugs due to injection or dilution. Drug Intell. Clin. Pharm. 1977, 11:417-419.
139. Yalkowsky S.H., Valvani S.C., Johnson B.W. In vitro method for detecting precipitation of parenteral formulations after injection. J. Pharm. Sci. 1983, 72:1014-1017.
140. Zangenberg N.H., Mullertz A., Gjelstrup Kristensen H., Hovgaard L. A dynamic in vitro lipolysis model II: evaluation of the model. Eur. J. Pharm. Sci. 2001, 14:237-244.
141. Zangenberg N.H., Mullertz A., Kristensen H.G., Hovgaard L. A dynamic in vitro lipolysis model I. Controlling the rate of lipolysis by continuous addition of calcium. Eur. J. Pharm. Sci. 2001, 14:115-122.